Xencor (XNCR) AI Stock Analysis

• Market Cap: $1.02B
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: 38.16%
• EPS Growth: 48.43%
• Country: US
• Employees: 250
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 71,323,044
• 10 Day Avg. Volume: 1,564,719
• 30 Day Avg. Volume: 1,334,755
• PEG Ratio: -0.09
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 13.53
• P/FCF Ratio: -7.18
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 2.41
• Enterprise Value/Gross Profit: 3.92
• Enterprise Value/Ebitda: -4.85
• 1Y Price Target: $22.25
• Price Target Upside: 58.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $15.00 ▲(7.14% Upside)

Xencor's overall stock score is driven by strong technical analysis indicators, suggesting positive market momentum. However, financial performance is hindered by profitability challenges and weak cash flow, while valuation metrics are unattractive due to negative earnings.

Positive Factors

Revenue Growth Potential

Xencor's positive revenue growth rate of 19.38% TTM suggests potential for expansion, driven by its innovative XmAb technology and partnerships.

Strong Balance Sheet

A low debt-to-equity ratio indicates financial stability, providing Xencor with flexibility to invest in R&D and withstand market fluctuations.

Innovative Technology Platform

The XmAb technology platform enhances drug efficacy and safety, positioning Xencor as a leader in biopharmaceutical innovation and attracting partnerships.

Negative Factors

Profitability Challenges

Negative profit margins indicate ongoing challenges in achieving profitability, which may hinder long-term financial sustainability and investor confidence.

Weak Cash Flow

Declining free cash flow growth suggests potential liquidity issues, limiting Xencor's ability to fund operations and invest in growth opportunities.

Negative Return on Equity

Negative ROE reflects inefficiencies in utilizing equity capital, potentially impacting investor returns and the company's ability to raise future capital.

Xencor Business Overview & Revenue Model

Company Description

Xencor, Inc. is a biopharmaceutical company focused on the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology platform to create novel therapeutics that enhance the efficacy and safety of antibody-based treatments. Xencor's pipeline includes multiple drug candidates that are in various stages of clinical development, targeting significant unmet medical needs in oncology and other therapeutic areas.

How the Company Makes Money

Xencor generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which include upfront payments, research funding, and milestone payments tied to the progression of drug candidates through clinical trials. Additionally, the company may earn royalties on future sales of products that are commercialized through these partnerships. Xencor also engages in licensing its XmAb technology platform to other companies, further contributing to its revenue streams. The success of its drug candidates in clinical trials and eventual commercialization are critical factors influencing its earnings.

Xencor Financial Statement Overview

Summary

Xencor's financial performance is mixed. While there is a positive revenue growth rate of 19.38%, the company struggles with profitability, as indicated by negative net profit and EBIT margins. The balance sheet is strong with low leverage, but cash flow issues persist, impacting liquidity.

Income Statement

Xencor's income statement shows a mixed performance. The company has experienced a positive revenue growth rate of 19.38% TTM, indicating potential growth. However, profitability metrics such as the net profit margin and EBIT margin are negative, reflecting ongoing challenges in achieving profitability. The gross profit margin remains high, suggesting efficient cost management at the gross level, but the negative net profit margin highlights significant expenses or losses further down the income statement.

Balance Sheet

The balance sheet reveals a relatively low debt-to-equity ratio of 0.11 TTM, indicating conservative leverage and a strong equity position. However, the return on equity is negative, suggesting that the company is not currently generating positive returns on its equity investments. The equity ratio is stable, reflecting a solid capital structure, but the negative ROE indicates challenges in profitability.

Cash Flow

Xencor's cash flow statement shows a decline in free cash flow growth by -18.63% TTM, which is concerning for future liquidity. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations relative to its net losses. The free cash flow to net income ratio is slightly above 1, suggesting some ability to cover net losses with free cash flow, but overall cash flow performance remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	146.36M	110.49M	168.34M	164.58M	275.11M	122.69M
Gross Profit	89.96M	110.49M	-85.26M	155.78M	267.62M	-47.11M
EBITDA	-72.79M	-186.17M	-125.87M	-72.16M	51.26M	-71.00M
Net Income	-138.75M	-232.62M	-126.09M	-55.18M	82.63M	-63.54M
Balance Sheet
Total Assets	868.81M	951.95M	952.69M	846.27M	838.21M	703.24M
Cash, Cash Equivalents and Short-Term Investments	386.78M	497.77M	593.73M	623.06M	334.11M	603.00M
Total Debt	69.27M	231.95M	83.43M	59.63M	33.97M	11.63M
Total Liabilities	243.50M	277.92M	283.56M	118.77M	104.71M	130.80M
Stockholders Equity	625.32M	677.61M	668.80M	727.50M	733.50M	572.44M
Cash Flow
Free Cash Flow	-143.67M	-208.28M	63.86M	-18.92M	-32.83M	-18.77M
Operating Cash Flow	-138.98M	-202.19M	85.11M	24.48M	-16.85M	-5.00M
Investing Cash Flow	126.06M	-7.87M	-111.06M	-119.72M	-46.25M	100.19M
Financing Cash Flow	12.08M	197.15M	26.18M	5.70M	43.04M	18.04M

Xencor Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XNCR, the sentiment is Positive. The current price of 14 is above the 20-day moving average (MA) of 13.99, above the 50-day MA of 11.59, and above the 200-day MA of 10.94, indicating a bullish trend. The MACD of 0.68 indicates Positive momentum. The RSI at 55.24 is Neutral, neither overbought nor oversold. The STOCH value of 47.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XNCR.

Xencor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	59 Neutral	$1.30B	34.05	15.02%	―	1128.17%	―
DNTH	55 Neutral	$1.32B	-10.20	-28.57%	―	-42.64%	-39.78%
XNCR	54 Neutral	$1.02B	-7.88	-19.61%	―	38.16%	48.43%
RLAY	54 Neutral	$1.18B	-3.52	-46.24%	―	-76.27%	22.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AUTL	48 Neutral	$368.61M	―	-52.18%	―	187.52%	26.32%
MRVI	46 Neutral	$732.89M	―	-55.41%	―	-22.52%	-37.00%

Xencor Corporate Events

Xencor Inc.’s XmAb541: A Promising Phase 1 Study in Advanced Solid Tumors

Study Overview: Xencor Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors.’ The study aims to assess the safety and tolerability of XmAb541, an investigational drug, and to determine an optimal dose for future research. This study is significant as it explores potential treatment options for various advanced solid tumors, including ovarian and endometrial cancers.

Xencor’s XmAb819 Study: A Promising Step in Cancer Treatment

Study Overview: Xencor Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma.’ The study aims to assess the safety and tolerability of XmAb®819, a treatment for patients with relapsed or refractory clear cell renal cell carcinoma, and to determine the minimum safe and biologically active dose.

Xencor’s Promising NSCLC Study: A Potential Game-Changer?

Study Overview: Xencor Inc. is conducting a Phase 1b/2 study titled A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer. The study aims to determine the optimal dose of vudalimab combined with chemotherapy and to assess its efficacy and safety compared to pembrolizumab plus chemotherapy in treating nonsquamous non-small cell lung cancer (NSCLC).

Xencor’s XmAb942 Study: A New Hope for Ulcerative Colitis?

Study Overview: Xencor Inc. is conducting a clinical study titled A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of XmAb942 in healthy volunteers and its efficacy in participants with ulcerative colitis. This study is significant as it explores potential new treatments for ulcerative colitis, a chronic inflammatory bowel disease.

Xencor Reports Initial Results from Phase 1 Studies

On October 24, 2025, Xencor, Inc. held a conference call to discuss initial results from its ongoing Phase 1 dose-escalation study of XmAb819, a bispecific T-cell engager for advanced clear cell renal cell carcinoma. The company also shared early data from the Phase 1 study of XmAb541 for ovarian cancer and germ cell tumors. These developments highlight Xencor’s continued progress in its oncology pipeline, potentially enhancing its competitive position in the market by advancing novel therapeutic candidates.

The most recent analyst rating on (XNCR) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.

Xencor’s XmAb808 Study: A New Frontier in Cancer Treatment

Study Overview: Xencor Inc. recently completed a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors.’ The study aimed to assess the safety and effectiveness of XmAb808, a novel therapeutic antibody, when used with pembrolizumab in treating advanced solid tumors. This research is significant as it explores new treatment avenues for challenging cancer types.

Xencor’s XmAb541 Study: A Promising Step in Cancer Treatment

Study Overview: Xencor Inc. is conducting a Phase 1 clinical trial titled ‘A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors.’ The study aims to assess the safety and tolerability of XmAb541, an investigational drug, and determine the optimal dose for further research. This study is significant as it explores potential new treatments for advanced solid tumors.

Xencor, Inc. Reports Revenue Growth Amidst Continued Losses

Xencor, Inc. is a clinical-stage biopharmaceutical company specializing in engineered antibody therapeutics for cancer and autoimmune diseases, leveraging its protein engineering capabilities to develop XmAb drug candidates.

Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology

In a recent update, Xencor Inc. has completed a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors.’ The study aimed to assess the safety and tolerability of XmAb541, a monoclonal bispecific antibody, and to determine optimal dosing for future research. This investigational drug is intended to improve outcomes in patients with advanced solid tumors.

Xencor Appoints Raymond Deshaies to Board of Directors

On July 31, 2025, Xencor announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies, a renowned biochemist and cell biologist with extensive experience in biotechnology and drug development, previously served as senior vice president of global research at Amgen Inc. His appointment is expected to bolster Xencor’s efforts in advancing its pipeline of XmAb drug candidates through clinical development, leveraging his deep understanding of biological mechanisms and track record of translating scientific insights into transformative medicines.

The most recent analyst rating on (XNCR) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.

Xencor’s XmAb819 Study: A Promising Step in Renal Cell Carcinoma Treatment

Study Overview: Xencor Inc. is conducting a Phase 1 study titled ‘A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma.’ The study aims to assess the safety and tolerability of XmAb819, a monoclonal bispecific antibody, in patients with advanced renal cell carcinoma, and to determine the minimum safe and biologically active dose.